Advertisement

Topics

Search Results for "Blue Oval Pill With 68 Taro"

04:03 EDT 25th August 2016 | BioPortfolio

Matching Channels

Blue hues

Von Willebrand's Disease

von Willebrand disease (vWD) is the most common hereditary coagulation abnormality described in humans, although it can also be acquired as a result of other medical conditions. It arises from a qua...

Matching News

Taro CEO Kal Sundaram to Return to Sun Pharma Headquarters by the End of 2016

HAWTHORNE, N.Y.–(BUSINESS WIRE)–Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) announced today that its CEO, Mr. Kal Sundaram, has infor...

Kal Sundaram appointed as chairman of Taro Pharmaceutical

Taro Pharmaceutical Industries Ltd. (Taro) announced that Dilip Shanghvi has resigned, effective April 18, as chairman and a member of Taro's board of directors in order to focus on other growth prior...

Taro's CEO Kal Sundaram to return to Sun Pharma by end of 2016

Taro Pharmaceutical Industries has announced that its CEO, Kal Sundaram, has informed Taro's board of directors of his intention to step down as CEO by the end of the current calendar year. Sundaram w...

Taro CEO Kal Sundaram to Return to Sun Pharma HQ

Taro Pharmaceutical announced that its CEO, Kal Sundaram, has expressed his intention to step down as CEO by the end of the year. Sundaram will return to India, to assume an executive position at Sun...

Taro CEO to step down, head to Sun Pharma HQ

David Salazar HAWTHORNE, N.Y. — Taro Pharmaceuticals on Thursday announced that its CEO Kal Sundaram would be stepping down as CEO at the end of 2016. Sundaram will be returning to India, where...

Taro Pharmaceutical Industries' (TARO) CEO Kal Sundaram on Q4 2016 Results - Earnings Call Transcript

S. aureus wall teichoic acid biosynthesis protein tarO (tarO)

In vitro and mouse studies identified inhibitors of S.

Taro CEO Kal Sundaram to return to Sun Pharma HQ by end-2016

Taro Pharmaceutical Industries announced today that its chief executive, Kalyanasundaram (Kal) Sundaram,…

Matching PubMed Articles

Two-step identification of taro (Colocasia esculenta cv. Xinmaoyu) using specific psbE-petL and simple sequence repeat-sequence characterized amplified regions (SSR-SCAR) markers.

Colocasia esculenta cv. Xinmaoyu is an eddoe-type taro cultivar local to Taicang, Jiangsu Province, China; it is characterized by its pure flavor, glutinous texture, and high nutritional value. Due to...

Bioethanol production from taro waste using thermo-tolerant yeast Kluyveromyces marxianus K21.

In the present study, evaluation and optimization of taro waste (TW), which was mainly composed of taro peels that contain many starch residues, as the main carbon source in medium were studied. The f...

Genetic Diversification and Dispersal of Taro (Colocasia esculenta (L.) Schott).

Taro (Colocasia esculenta (L.) Schott) is widely distributed in tropical and sub-tropical areas. However, its origin, diversification and dispersal remain unclear. While taro genetic diversity has bee...

Effects of the Chinese herbal formula "Zuojin Pill" on the pharmacokinetics of dextromethorphan in healthy Chinese volunteers with CYP2D6*10 genotype.

Zuojin Pill has been shown to inhibit the cytochrome P450 (CYP) 2D6 isoenzyme in vitro. In Chinese individuals, CYP 2D6*10 is the most common allele with reduced enzyme activity. In this study, we inv...

Linagliptin and pioglitazone combination therapy versus monotherapy with linagliptin or pioglitazone: A randomised, double-blind, parallel-group, multinational clinical trial.

Linagliptin plus pioglitazone single-pill combinations were evaluated. Patients (n = 936) with insufficient glycaemic control, despite lifestyle interventions, were randomised for 30 weeks to ei...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement